{
    "nct_id": "NCT05983432",
    "official_title": "A Phase 1 Study Evaluating the Safety, Tolerability, and Efficacy of BL-B01D1 in Subjects With Metastatic or Unresectable Non-Small Cell Lung Cancer and Other Solid Tumors",
    "inclusion_criteria": "1. Sign informed consent\n2. Expected survival > or = 3months\n3. Has histologically documented, incurable, locally advanced or metastatic epithelial origin malignant cancer, priority to include the following tumor types: Non-Small Cell Lung Cancer, HER2- breast cancer, esophageal cancer, Small Cell Lung Cancer, and Nasopharyngeal Cancer\n4. Agree to provide a tumor sample\n5. Has at least one measurable lesion based on RECIST 1.1\n6. Has an Eastern Cooperative Oncology Group performance status (ECOG PS) 0 to 1\n7. Toxicity of previous antitumor therapy has returned to level ≤1 as defined by NCI-CTCAE V5.0 (except for asymptomatic laboratory abnormalities such as elevated ALP, hyperuricemia, elevated serum or plasma amylase/lipase, and elevated blood glucose; except for toxicity that the investigator determined to have no safety risk, such as alopecia, grade 2 peripheral neurotoxicity, hypothyroidism stabilized by hormone replacement therapy, etc.)\n8. Has no serious cardiac dysfunction, left ventricular ejection fraction ≥50%.\n9. Has adequate organ function before registration\n10. Coagulation function: international normalized ratio (INR) ≤1.5×ULN, and activated partial thromboplastin time (APTT) ≤1.5 ULN\n11. Urinary protein ≤2+ or ≤1000mg/24 hours\n12. For premenopausal women with childbearing potential, a pregnancy test must be taken within 7 days prior to the start of treatment. Serum or urine pregnancy must be negative and must be non-lactating\n13. Must agree to use adequate barrier contraceptive measures during the treatment and 6 months after the end of treatment for all subjects (regardless of gender)\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "1. Chemotherapy, biological therapy, immunotherapy, radical radiotherapy, major surgery, targeted therapy and other anti-tumor therapy within 4 weeks or 5 half-lives (whichever is shorter) prior to the first administration\n2. Subjects with history of severe heart disease\n3. Active autoimmune diseases and inflammatory diseases\n4. Other malignant tumors were diagnosed within 5 years\n5. Subjects with poorly controlled hypertension\n6. Subjects have Grade 3 lung disease or a history of interstitial lung disease\n7. Unstable thrombotic events such as deep vein thrombosis, arterial thrombosis, and pulmonary embolism requiring therapeutic intervention within the previous 6 months before screening\n8. Symptoms of active central nervous system metastasis\n9. Subjects who have a history of allergies to recombinant humanized antibodies or human mouse chimeric antibodies or any of the components of BL-B01D1\n10. Subjects have a history of autologous or allogeneic stem cell transplantation\n11. Known HIV, active tuberculosis, active Hepatitis B virus infection or active Hepatitis C virus infection\n12. Subjects with active infections requiring systemic treatment\n13. Participated in another clinical trial within 4 weeks prior to participating in the study\n14. Other conditions that the investigator believes that it is not suitable for participating in this clinical trial\n15. Subjects with prolonged QT interval (QTc >470 msec), complete left bundle branch block, Grade 3 atrioventricular block\n16. Has received treatment with anthracyclines with a cumulative dose exceeding 360 mg/m2",
    "miscellaneous_criteria": ""
}